European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
NEW YORK, March 04, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/ESPR-Info-Request-Form-1062. There is no cost or obligation to you.
The complaint alleges that Defendants issued false and misleading statements regarding the Company’s business and prospects, including that there was no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion reported to investors material events from an August 2015 meeting with the FDA; the Company stated that during the meeting it was informed by the FDA that the Company would not have to complete a CVOT to gain approval of ETC-1002. Then in a September 28, 2015 news release the Company noted that the FDA had actually “encouraged the Company to initiate a cardiovascular outcomes trial promptly” and it may be necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion Therapeutics you have until March 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ESPR-Info-Request-Form-1062.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
